ABEONA THERAPEUTICS INC (ABEO)
Health Care · Cell and gene therapy for rare genetic diseases · NASDAQ
Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds.
What ABEONA THERAPEUTICS INC does
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The company achieved a major milestone with FDA approval of ZEVASKYN® (prademagene zamikeracel), the first and only FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN® is manufactured at the company's cGMP facility in Cleveland, Ohio, and administered through a network of qualified treatment centers. Beyond RDEB, Abeona is developing a pipeline of AAV-based gene therapies targeting ophthalmic diseases using its proprietary AIM™ capsid technology platform.
Themes: ["Cell and gene therapy","AAV gene therapy / AAV vectors","Rare genetic diseases / orphan drugs","RDEB (recessive dystrophic epidermolysis bullosa)","Ophthalmic / ophthalmology gene therapy","Biomanufacturing / cGMP manufacturing"]
Fundamentals
- Price$7.12 as of 2026-07-09 close
- Market cap$397M as of 2026-07-10
- 1-year return+22.1% as of 2026-07-09 close
- P/E6.00 as of 2026-07-10
- Net margin+490.4% as of 2026-07-10
- Gross margin+73.5% as of 2026-07-10
- ROE+41.4% as of 2026-07-10
- Debt / equity0.12 as of 2026-07-10
- Revenue growth (YoY)+60.4% as of 2026-07-10
- Revenue CAGR (3y)+18.0% SEC XBRL
- Beta1.33 as of 2026-07-10
Key risks (from latest filing)
["Ability to successfully manufacture and supply sufficient ZEVASKYN® batches to meet patient demand and activate additional qualified treatment centers","Market acceptance and commercialization success of ZEVASKYN® and pipeline candidates; regulatory approval and ongoing FDA compliance for product candidates","Dependence on additional equity financing and dilution risk from at-the-market offerings; macroeconomic uncertainty and U.S. trade policy changes affecting operations"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.